The Ministry of Health and Community Protection has decided to withdraw two operations from the pharmaceutical company Gupisone Syrup Lot No: 0001 & 0002, produced by Julphar, which is used to treat arthritis, immune system disorders and asthma, because the preservative is below the permissible limits.
According to the administrative circular issued by the Assistant Undersecretary for Public Health Policy and Licenses, the head of the Higher Committee for Drug Awakening Dr. Amin Hussein Al Amiri, the Ministry, after reviewing the Federal Law No. 4 of 1983, on the profession of pharmacy and pharmaceutical institutions, Ministerial Decision No. 366 of 2010 on the announcement of withdrawal Suspend, stop or prevent the circulation of pharmaceutical and medical products, and on the basis of public interest, decided to withdraw two operations of the said pharmaceutical.
According to the ministry, the laboratory of Quality Control and Research of Medical Products of the Ministry of Health and Community Protection analyzed the product in order to verify the quality. The results of laboratory analysis showed that the percentage of preservative is less than the permissible limits.
The ministry called on the manufacturer to withdraw the two operations from the public and private sectors, stressing that all health care practitioners in the country should not use the two operations if they have any, and pharmacies must stop their payments and return them to the supplier.
She stressed that in the event of any health complications resulting from the use of medication, the need to communicate with the Ministry to take appropriate remedial action.